153 results about "Vascularizes" patented technology

A system and method for opening a lumen in an occluded blood vessel, e.g., a coronary bypass graft, of a living being's vascular system. The system introduces an infusate liquid at a first flow rate to the occluded portion of the blood vessel, and withdraws that liquid and some blood at a second and higher flow rate. This action creates a differential flow in the occluded blood vessel portion and thereby prevent particles of occlusive material from flowing into any upstream blood vessel or downstream blood vessel in said living being's vascular system.

Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and / or thick structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, wherein the first and second molds or polymer scaffolds have means defining microchannels positioned toward the semi-permeable membrane, wherein the first and second molds or polymer scaffolds are fastened together; and (b) animal cells. Methods for producing complex, three-dimensional tissues or organs from tissue lamina are also provided.

Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and / or thick structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, wherein the first and second molds or polymer scaffolds have means defining microchannels positioned toward the semi-permeable membrane, wherein the first and second molds or polymer scaffolds are fastened together; and (b) animal cells. Methods for producing complex, three-dimensional tissues or organs from tissue lamina are also provided.

A computerized method for determining an objective tumor response to an anti-cancer therapy using one or more cross-sectional images can comprise receiving one or more cross-sectional images that comprise one or more cross-sectional slices of digital medical image data and identifying one or more target lesions within the one or more cross-sectional images. The method can also comprise analyzing at least one of the target lesions with an image-processing module configured to identify a total range of pixel intensities and restrict the total range of pixel intensities to a first restricted range that corresponds to pixel intensities representative of vascularized tumor. Further still, the method can comprise deriving a vascular tumor burden for the at least one of the one or more target lesions and determining the objective tumor response for the at least one of the one or more target lesions based on the vascular tumor burden.

Disclosed are improved methods and compositions for use in light-based in vivo imaging and treatment. The techniques described involve the use of low-scattering, oxygen-carrying blood substitutes in imaging and treatment methods, including OCT imaging. The invention has particular advantages in imaging within the cardiovascular system and highly vascularized or oxygen-dependent tissues.

The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+ / NKX2.5− / KDR−. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and / or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and / or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors.